Related references
Note: Only part of the references are listed.Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1Positive, Advanced NonSmall-Cell Lung Cancer in the KEYNOTE-010 Study
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study
Ilya Tsimafeyeu et al.
SCIENTIFIC REPORTS (2020)
Molecular profiling of non-small cell lung cancer
Marika L. Forsythe et al.
PLOS ONE (2020)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors
Hisao Imai et al.
THORACIC CANCER (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang et al.
MOLECULAR CANCER (2019)
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2017)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma
Min-Kyung Yeo et al.
HUMAN PATHOLOGY (2017)
Immunotherapy in Non-Small Cell Lung Cancer Treatment Current Status and the Role of Imaging
Brett W. Carter et al.
JOURNAL OF THORACIC IMAGING (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Correlation between messenger RNA expression and protein expression of immune checkpoint associated molecules in bladder urothelial carcinoma: A retrospective study
Constance Le Goux et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Lihu Gu et al.
PLOS ONE (2017)
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
Minghui Zhang et al.
SCIENTIFIC REPORTS (2017)
Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis
D. Li et al.
EJSO (2017)
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Masaki Shimoji et al.
LUNG CANCER (2016)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh et al.
MODERN PATHOLOGY (2015)
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
Yanna Tang et al.
ONCOTARGET (2015)
PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation
Nemanja Rodic et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma
Yang Zhang et al.
ONCOTARGETS AND THERAPY (2014)
The Impact of EGFR Mutation Status on Outcomes in Patients With Resected Stage I Non-Small Cell Lung Cancers
Benjamin Izar et al.
ANNALS OF THORACIC SURGERY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer
Stephanie Cardarella et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation
Rathi N. Pillai et al.
CURRENT ONCOLOGY REPORTS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Large-scale discovery and genotyping of single-nucleotide polymorphisms in the mouse
K Lindblad-Toh et al.
NATURE GENETICS (2000)
Share Paper
